Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases. Aim: To investigate the timing, efficacy and safety of radiotherapy in patients with EGFR positive brain metastases treated with armatinib alone or combined with stereotactic radiotherapy. Method: Almonertinib: specification 55mg/tablet; The dosage is 110 mg / day (2 tablets / day) orally once a day; SBRT: 3-5 doses of 27-40 Gy

Trial Details

NCT ID
NCT05800223
Phase
PHASE3
Sponsor
Shanghai Cancer Hospital, China
Status
RECRUITING
Cancer Type
Brain Cancer
Locations (sample)
  • Shanghai, Shanghai Municipality, China

Key Eligibility Criteria

  • aged 18 years or older (including 18 years) and up to 75 years (including 75 years)
  • histologically confirmed NSCLC (by AJCC 8th edition lung cancer staging criteria)
  • asymptomatic or minimally symptomatic brain metastases (i.e., headache, nausea, or seizures responding to dexamethasone/analgesic/antiepileptic age…
  • brain metastases must meet the following criteria on diagnostic MRI: at least one lesion that can be classified as measurable disease according to …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →